08:05 AM EDT, 03/24/2026 (MT Newswires) -- Fennec Pharmaceuticals ( FENC ) , up 3.9% in U.S. pre-market trade, said Tuesday that fourth-quarter net loss widened as net sales rose 75%.

Net loss widened to US$5.1 million, or US$0.17 per share, compared with net loss of US$1.6 million, or US$0.06 per share, in the prior year period. Analysts polled by FactSet had expected a profit of US$0.04 per share.

Selling and general expenses jumped to US$6.1 million from US$3.9 million in the prior year period, due to higher payroll and marketing expenses as Fennec expands its commercial team for greater outreach to community oncology centers and the adolescent and young adult (AYA) population.

Net product sales jumped 75% to US$13.8 million over the same period, but missed the US$14.7 million forecast.

Fennec shares were last seen up US$0.29, to US$7.74, in New York trading.